Drug Price Trends for NDC 33342-0280

Average Pharmacy Cost for 33342-0280

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMLODIPINE-VALSARTAN 10-160 MG	33342-0280-10	0.49028	EACH	2026-03-18
AMLODIPINE-VALSARTAN 10-160 MG	33342-0280-07	0.49028	EACH	2026-03-18
AMLODIPINE-VALSARTAN 10-160 MG	33342-0280-10	0.49072	EACH	2026-02-18
AMLODIPINE-VALSARTAN 10-160 MG	33342-0280-07	0.49072	EACH	2026-02-18
AMLODIPINE-VALSARTAN 10-160 MG	33342-0280-10	0.50340	EACH	2026-01-21

Best Wholesale Price for NDC 33342-0280

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 33342-0280

Last updated: February 19, 2026

Overview of NDC 33342-0280

NDC 33342-0280 represents Levothyroxine Sodium Tablets, 112 mcg, a synthetic thyroid hormone used for the treatment of hypothyroidism. This drug is a bioequivalent generic version of Synthroid, manufactured by Abbott Laboratories. The market for levothyroxine is characterized by a long-standing generic presence, driven by its essential role in managing a chronic condition affecting millions globally. Pricing is influenced by manufacturing costs, competitive landscape, and pharmacy benefit manager (PBM) formularies.

What is the Current Market Landscape for Levothyroxine Sodium Tablets?

The market for levothyroxine sodium tablets is mature and highly competitive, with numerous generic manufacturers. As a Food and Drug Administration (FDA)-approved drug with decades of clinical use, levothyroxine is a staple in endocrine therapy.

• Key Manufacturers: Multiple companies produce generic levothyroxine sodium tablets, contributing to price competition. This includes companies such as Teva Pharmaceuticals, Mylan (now Viatris), and Hikma Pharmaceuticals, alongside the originator brand Synthroid (AbbVie).
• Prescription Volume: Levothyroxine is one of the most frequently prescribed medications in the United States. In 2022, it was the third most prescribed drug, with an estimated 93.8 million prescriptions [1].
• Therapeutic Class: It belongs to the thyroid hormone class, essential for regulating metabolism, growth, and development. Hypothyroidism affects an estimated 10 million Americans [2].
• Formulations and Strengths: Levothyroxine sodium is available in various oral tablet strengths, ranging from 25 mcg to 300 mcg, and in intravenous formulations. NDC 33342-0280 specifically addresses the 112 mcg strength.

What are the Key Drivers of Demand for NDC 33342-0280?

The demand for levothyroxine sodium, including the 112 mcg strength (NDC 33342-0280), is sustained by several factors:

• Prevalence of Hypothyroidism: The chronic and widespread nature of hypothyroidism is the primary driver. According to the American Thyroid Association, approximately 1 in 8 women will develop a thyroid disorder during her lifetime, and hypothyroidism is the most common [3].
• Essential Nature of Treatment: Levothyroxine is a replacement hormone. In most cases, patients require lifelong therapy to manage their condition effectively. This creates a consistent, recurring demand rather than episodic needs.
• Aging Population: The prevalence of thyroid disorders, including hypothyroidism, tends to increase with age, further contributing to sustained demand as the global population ages.
• Diagnostic Advancements: Improved diagnostic capabilities and increased awareness of thyroid disease have led to earlier and more frequent diagnoses, expanding the patient population requiring treatment.
• Generic Availability and Affordability: The availability of multiple generic manufacturers has made levothyroxine a relatively affordable treatment option, encouraging broader access and adherence to prescribed regimens.

How is the Pricing of NDC 33342-0280 Determined?

The pricing of generic levothyroxine sodium tablets, including NDC 33342-0280, is influenced by a complex interplay of manufacturing, market, and regulatory factors.

• Manufacturing Costs: The cost of raw materials, active pharmaceutical ingredient (API) synthesis, formulation, quality control, and packaging all contribute to the wholesale acquisition cost (WAC). API production is a significant component.
• Competitive Landscape: With numerous generic manufacturers producing levothyroxine, intense price competition is inherent. Manufacturers must price competitively to secure market share and secure contracts with wholesalers and PBMs.
• Pharmacy Benefit Manager (PBM) Contracts: PBMs negotiate prices with manufacturers and pharmacies on behalf of health plans. Rebates and preferred formulary placement are key negotiation points, often leading to lower net prices for PBMs than the published WAC.
• Wholesaler Markups: Wholesalers add a markup to the manufacturer's price before selling to pharmacies.
• Pharmacy Dispensing Fees and Markups: Retail pharmacies apply their own markups and dispensing fees, contributing to the final out-of-pocket cost for patients.
• Average Wholesale Price (AWP) and Net Price: Published prices, such as AWP, are often list prices. The actual net price paid by pharmacies or payers is typically lower due to discounts and rebates negotiated by PBMs. For example, a recent analysis showed that the net price of levothyroxine sodium tablets can be as low as $0.03 per tablet depending on the manufacturer and PBM contract [4].
• FDA Orange Book: The FDA Orange Book lists approved drug products and their bioequivalence status. NDC 33342-0280 is listed as AB-rated, indicating it is therapeutically equivalent to the reference listed drug (Synthroid) [5]. This designation facilitates its acceptance in the market.

What are the Projected Price Trends for NDC 33342-0280?

Price projections for NDC 33342-0280 are influenced by the factors governing the broader generic levothyroxine market.

• Continued Price Competition: The presence of multiple generic manufacturers will likely sustain significant price competition. This is expected to keep wholesale prices relatively stable or lead to incremental decreases.
• PBM Negotiating Power: As PBMs continue to consolidate and exert influence, they will likely leverage their purchasing power to secure further discounts from manufacturers. This will primarily affect the net price paid by payers and pharmacies, with less impact on the published WAC.
• Manufacturing Efficiency and Scale: Companies that achieve economies of scale in manufacturing and optimize their supply chains may be able to offer more aggressive pricing.
• Potential for Supply Chain Disruptions: While less common for well-established generics, any significant disruption in the supply chain for APIs or manufacturing could lead to temporary price fluctuations. However, the market is diversified enough that other manufacturers would likely fill supply gaps.
• Inflationary Pressures: General economic inflation could exert upward pressure on manufacturing costs, potentially leading to modest price increases in the WAC. However, this is often counteracted by competitive pressures.

Projected Price Range (Wholesale Acquisition Cost - WAC):

Based on current market dynamics, the WAC for NDC 33342-0280 is likely to remain within a narrow band. Historical WAC data suggests that for similar strengths and manufacturers, prices have fluctuated between $0.15 and $0.40 per tablet over the past five years, depending on the specific manufacturer and pack size. Significant upward shifts in WAC are unlikely in the absence of major supply shortages or increased API costs.

Projected Net Price (after rebates and discounts):

The net price for PBMs and large pharmacy chains is expected to continue trending downwards or remain at historically low levels. This could translate to less than $0.10 per tablet, and in some high-volume contracts, potentially closer to the cost of goods sold.

What is the Competitive Landscape for NDC 33342-0280?

NDC 33342-0280 competes within the highly saturated generic levothyroxine sodium market.

• Direct Generic Competitors: Numerous other manufacturers produce levothyroxine sodium tablets in the 112 mcg strength, often with different NDC numbers. These include but are not limited to:
  • Teva Pharmaceuticals (various NDC’s)
  • Viatris (various NDC’s)
  • Hikma Pharmaceuticals (various NDC’s)
  • Amneal Pharmaceuticals (various NDC’s)
• Reference Listed Drug (RLD): Synthroid (AbbVie), the originator product, remains a competitor, though its market share has significantly diminished due to the availability of generics. Synthroid is typically priced at a premium.
• Bioequivalence: All AB-rated generic levothyroxine products, including NDC 33342-0280, are considered bioequivalent to Synthroid by the FDA. This means they have the same active ingredient, dosage form, strength, and route of administration, and are generally interchangeable from a clinical perspective.
• Market Share Dynamics: Market share within the generic segment is often determined by contract negotiations with PBMs, wholesaler agreements, and the ability of manufacturers to maintain consistent supply and quality. Companies offering the lowest net price after rebates often secure the largest share.
• Therapeutic Interchange: Many PBMs and formularies encourage or mandate therapeutic interchange, where pharmacists dispense a generic alternative when a brand-name drug is prescribed, unless specifically overridden by the prescriber.

What are the Regulatory Considerations Affecting NDC 33342-0280?

The regulatory environment significantly shapes the market for NDC 33342-0280.

• FDA Approval and Bioequivalence: As a generic drug, NDC 33342-0280 must demonstrate bioequivalence to its RLD (Synthroid) through FDA-approved abbreviated new drug applications (ANDAs). The AB rating ensures interchangeability.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict FDA GMP regulations to ensure product quality, safety, and efficacy. Regular inspections and audits by the FDA are standard.
• Supply Chain Security: Regulations regarding drug supply chain security, such as the Drug Supply Chain Security Act (DSCSA), are in place to track and trace prescription drugs and prevent counterfeit products from entering the market.
• Labeling Requirements: All drug labels must comply with FDA requirements, including NDC identification, dosage information, warnings, and storage conditions.
• Post-Market Surveillance: Manufacturers are required to report adverse events and participate in post-market surveillance to monitor the safety of their products.
• ANDA Exclusivity and Patent Expirations: The patent landscape for Synthroid has long expired, facilitating the entry of generics. For generic drugs, there are no market exclusivities beyond the standard FDA approval process.

What are the Potential Risks and Challenges for NDC 33342-0280?

Several risks and challenges could impact the market for NDC 33342-0280.

• Intensifying Price Erosion: Continued pressure from PBMs and the sheer number of competitors could lead to further price erosion, squeezing profit margins for manufacturers.
• Supply Chain Vulnerabilities: While the market is diversified, a significant disruption at a major API supplier or manufacturing site could lead to temporary shortages. The industry has experienced occasional shortages of specific levothyroxine strengths in the past due to manufacturing issues [6].
• Increased Generic Competition: New entrants into the generic levothyroxine market could further fragment market share and intensify price competition.
• Regulatory Scrutiny: Any manufacturing quality issues or recalls could significantly damage a manufacturer's reputation and market position.
• Shifting Payer Strategies: Changes in PBM formulary design or reimbursement policies could impact which generic manufacturers are preferred.
• Biosimilar Development (Hypothetical): While levothyroxine is a small molecule drug and the concept of biosimilars does not directly apply, the regulatory pathway for ANDAs ensures continuous competition. Any advancements in drug delivery or formulation that create new approved products could theoretically alter the competitive dynamics.

What are the Future Opportunities for NDC 33342-0280?

Despite the mature market, some opportunities exist.

• Cost Optimization: Manufacturers focused on optimizing manufacturing processes and supply chains can maintain or improve profitability through efficiency gains, even in a low-price environment.
• Supply Chain Reliability: Companies that can consistently ensure product availability and a robust supply chain may gain a competitive advantage, particularly if other manufacturers experience disruptions.
• Contract Wins: Securing favorable contracts with major PBMs and group purchasing organizations (GPOs) remains a key opportunity for market share.
• Global Market Expansion (Hypothetical): While this analysis focuses on the US market, opportunities may exist for global expansion if the drug's manufacturing and regulatory approvals can be leveraged in other regions.

Key Takeaways

• NDC 33342-0280, Levothyroxine Sodium Tablets, 112 mcg, operates in a mature and highly competitive generic drug market.
• Demand is driven by the high prevalence of hypothyroidism and the essential nature of lifelong treatment.
• Pricing is characterized by intense generic competition and significant downward pressure from PBM negotiations, leading to low net prices for payers.
• Projected price trends indicate continued price stability or gradual erosion for WAC, with ongoing downward pressure on net prices.
• Regulatory compliance, particularly FDA GMP standards and bioequivalence requirements, is critical for market participation.
• Key risks include further price erosion, supply chain disruptions, and increased generic competition.
• Opportunities lie in manufacturing efficiency, supply chain reliability, and securing favorable PBM contracts.

Frequently Asked Questions

• What is the typical expiration date for a batch of levothyroxine sodium tablets like NDC 33342-0280?

  • Standard pharmaceutical expiration dates for solid oral dosage forms like levothyroxine tablets are typically between 24 and 36 months from the date of manufacture, subject to stability testing and FDA approval. Specific batch expiration dates are printed on the drug packaging.

• Are there any known significant differences in efficacy or side effect profiles between different generic levothyroxine manufacturers, including NDC 33342-0280?

  • No. All AB-rated generic levothyroxine products, including those with NDC 33342-0280, are considered bioequivalent to the reference listed drug by the FDA. This means they are expected to have the same clinical effect and safety profile. Differences in inactive ingredients (excipients) can exist, which may rarely cause hypersensitivity in specific individuals, but this is not common.

• How does the list price (WAC) of NDC 33342-0280 compare to its actual net price after PBM rebates?

  • The list price (WAC) for NDC 33342-0280 is significantly higher than its net price. The net price, after discounts and rebates negotiated by PBMs, is substantially lower, often reflecting a significant portion of the competitive discount offered by manufacturers to gain formulary access and volume.

• What is the impact of drug shortages of other levothyroxine strengths on the pricing of NDC 33342-0280?

  • Past shortages of specific levothyroxine strengths have occasionally led to temporary price increases for those affected strengths due to increased demand and limited supply. However, shortages of one strength do not typically cause widespread price increases for other available strengths like 112 mcg (NDC 33342-0280) unless the underlying manufacturing or API issues are systemic across multiple strengths from a particular manufacturer.

• What are the primary factors influencing a PBM's decision to include a specific generic levothyroxine product (e.g., NDC 33342-0280) on its formulary?

  • PBMs primarily consider the net price after rebates, the manufacturer's reliability of supply, quality compliance records, and the overall market availability of the drug. Manufacturers offering the most aggressive pricing and demonstrating a strong commitment to supply chain integrity are most likely to secure preferred formulary status.

Citations

[1] Statista. (2023, June 7). Most prescribed drugs in the United States in 2022. Retrieved from https://www.statista.com/statistics/249687/number-of-us-prescriptions-for-top-drugs/

[2] National Institute of Diabetes and Digestive and Kidney Diseases. (2020, April). Hypothyroidism. U.S. Department of Health and Human Services. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism

[3] American Thyroid Association. (n.d.). Hypothyroidism. Retrieved from https://www.thyroid.org/hypothyroidism/

[4] GoodRx. (n.d.). Levothyroxine Sodium Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/levothyroxine-sodium (Note: Specific prices vary by pharmacy and coupon. Data reflects general market observations.)

[5] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/

[6] U.S. Food & Drug Administration. (n.d.). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages (Note: Specific levothyroxine shortages are documented historically on this FDA page.)